185 related articles for article (PubMed ID: 27162322)
1. Prospective cohort study of febrile neutropenia in breast cancer patients with neoadjuvant and adjuvant chemotherapy: CSPOR-BC FN study.
Ishikawa T; Sakamaki K; Narui K; Kaise H; Tsugawa K; Ichikawa Y; Mukai H;
Jpn J Clin Oncol; 2016 Jul; 46(7):692-5. PubMed ID: 27162322
[TBL] [Abstract][Full Text] [Related]
2. Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study.
Ishikawa T; Sakamaki K; Narui K; Nishimura H; Sangai T; Tamaki K; Hasegawa Y; Watanabe KI; Suganuma N; Michishita S; Sugae S; Aihara T; Tsugawa K; Kaise H; Taira N; Mukai H;
Breast; 2021 Apr; 56():70-77. PubMed ID: 33631458
[TBL] [Abstract][Full Text] [Related]
3. Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.
Bacrie J; Laurans M; Iorio P; Fourme E; Volters AB; Bozec L; Lerebours F; Dubot C; Bensaoula O; Benzidane B; Pierga JY; Lefeuvre D
Support Care Cancer; 2018 Dec; 26(12):4097-4103. PubMed ID: 29855772
[TBL] [Abstract][Full Text] [Related]
4. Febrile Neutropenia Rates According to Body Mass Index and Dose Capping in Women Receiving Chemotherapy for Early Breast Cancer.
Lote H; Sharp A; Redana S; Papadimitraki E; Capelan M; Ring A
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):597-603. PubMed ID: 26936608
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of the pre-prescription of garenoxacin in comparison to moxifloxacin for low-risk febrile neutropenia in breast cancer patients undergoing adjuvant and neoadjuvant chemotherapy.
Takahashi M; Takahashi K; Ogawa K; Takashima T; Asano Y; Kashiwagi S; Noda S; Onoda N; Ohira M; Nagayama K
Support Care Cancer; 2019 Aug; 27(8):2829-2836. PubMed ID: 30547304
[TBL] [Abstract][Full Text] [Related]
6. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
8. Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer.
Adjogatse D; Thanopoulou E; Okines A; Thillai K; Tasker F; Johnston SR; Harper-Wynne C; Torrisi E; Ring A
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):692-6. PubMed ID: 24909701
[TBL] [Abstract][Full Text] [Related]
9. Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.
Charehbili A; de Groot S; van der Straaten T; Swen JJ; Pijl H; Gelderblom H; van de Velde CJ; Nortier JW; Guchelaar HJ; Kroep JR
Pharmacogenomics; 2015; 16(11):1267-76. PubMed ID: 26289095
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
11. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of the Risk Factors of Febrile Neutropenia Among 72 Women Receiving FEC in Early Breast Cancer Chemotherapy].
Ishii N; Fujimori T; Kasagawa T; Udagawa I
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1555-1557. PubMed ID: 28133055
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim.
Collins JM; Fleming GF; Christ TN
J Oncol Pharm Pract; 2019 Jul; 25(5):1112-1118. PubMed ID: 29768957
[TBL] [Abstract][Full Text] [Related]
14. Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea.
Kim HS; Lee SY; Kim JW; Choi YJ; Park IH; Lee KS; Seo JH; Shin SW; Kim YH; Kim JS; Park KH
Oncology; 2016; 91(5):274-282. PubMed ID: 27623006
[TBL] [Abstract][Full Text] [Related]
15. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
[TBL] [Abstract][Full Text] [Related]
16. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
[TBL] [Abstract][Full Text] [Related]
17. The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.
Fujiwara T; Kenmotsu H; Naito T; Kawamura T; Mamesaya N; Kotake M; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Taira T; Murakami H; Omae K; Mori K; Endo M; Takahashi T
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1229-1237. PubMed ID: 28455585
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
Younis T; Rayson D; Jovanovic S; Skedgel C
Breast Cancer Res Treat; 2016 Oct; 159(3):425-32. PubMed ID: 27572552
[TBL] [Abstract][Full Text] [Related]
19. Clinical Verification on the Predictors for Febrile Neutropenia in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Goto W; Kashiwagi S; Matsuoka K; Iimori N; Kouhashi R; Yabumoto A; Takada K; Asano Y; Tauchi Y; Ogisawa K; Morisaki T; Shibutani M; Tanaka H; Maeda K
Anticancer Res; 2023 Jan; 43(1):247-254. PubMed ID: 36585206
[TBL] [Abstract][Full Text] [Related]
20. Weak circadian rhythm increases neutropenia risk among breast cancer patients undergoing adjuvant chemotherapy.
Li W; Kwok CC; Chan DC; Wang F; Tse LA
Breast Cancer Res Treat; 2018 Apr; 168(2):483-493. PubMed ID: 29230661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]